Wang Dan, Tian Yanqiu, Feng Wenhua, Zhao Li, Zhao Mingyi, Liu Ju, Wang Qiuyu
aDepartment of Pharmacy bDepartment of Life science, Liaoning University cKey Laboratory of Reproductive Health and Medical Genetics, National Health and Family Planning Commission, Liaoning Province Research Institute of Family Planning dDepartment of Oncology, Affiliated Shengjing Hospital of China Medical University eShenyang Children's Hospital, Shenyang, China.
Anticancer Drugs. 2017 Jul;28(6):603-612. doi: 10.1097/CAD.0000000000000500.
Pseudolaric acid B (PAB) is the most active constituent extracted from the bark of Pseudolarix kaempferi, which has been used as an antifungal remedy in traditional Chinese medicine. It is reported to have cytotoxicity to many tumor cell lines. In this study, we investigated the effects of PAB against human endometrial cancer Ishikawa cells. We found that PAB inhibited Ishikawa cell proliferation, and induced cell apoptosis and G2/M phase arrest through a mechanism involving AKT-GSK-3β and ERK1/2 signaling pathways. PAB also suppressed the Ishikawa cell adhesion, invasion, migration, and colony formation ability by increasing the expression of E-cadherin, Ezrin, and Kiss-1, and decreasing the expression of matrix metalloproteinase-9 and vascular endothelial growth factor. Taken together, these data indicated that PAB can be expected to be a novel treatment agent for endometrial cancer therapy.
土荆皮酸B（PAB）是从金钱松树皮中提取的最具活性的成分，在中国传统医学中一直被用作抗真菌药物。据报道，它对许多肿瘤细胞系具有细胞毒性。在本研究中，我们研究了PAB对人子宫内膜癌Ishikawa细胞的影响。我们发现PAB抑制Ishikawa细胞增殖，并通过涉及AKT-GSK-3β和ERK1/2信号通路的机制诱导细胞凋亡和G2/M期阻滞。PAB还通过增加E-钙黏蛋白、埃兹蛋白和Kiss-1的表达，以及降低基质金属蛋白酶-9和血管内皮生长因子的表达，抑制Ishikawa细胞的黏附、侵袭、迁移和集落形成能力。综上所述，这些数据表明PAB有望成为一种新型的子宫内膜癌治疗药物。
